These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10463706)

  • 1. Association of the CCR5delta32 mutation with improved response to antiretroviral therapy.
    Valdez H; Purvis SF; Lederman MM; Fillingame M; Zimmerman PA
    JAMA; 1999 Aug; 282(8):734. PubMed ID: 10463706
    [No Abstract]   [Full Text] [Related]  

  • 2. Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen.
    Brumme ZL; Henrick BM; Brumme CJ; Hogg RS; Montaner JS; Harrigan PR
    Antivir Ther; 2005; 10(7):849-53. PubMed ID: 16312181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antiretroviral therapy in patients infected with HIV-1].
    Corti ME
    Medicina (B Aires); 1998; 58 Suppl 1():49-56. PubMed ID: 9674248
    [No Abstract]   [Full Text] [Related]  

  • 4. CCR5 delta32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients.
    Guérin S; Meyer L; Theodorou I; Boufassa F; Magierowska M; Goujard C; Rouzioux C; Debré P; Delfraissy JF;
    AIDS; 2000 Dec; 14(17):2788-90. PubMed ID: 11125899
    [No Abstract]   [Full Text] [Related]  

  • 5. In vivo cell-mediated immunity in subjects with undetectable viral load on protease inhibitor-based versus non-protease inhibitor-based highly active antiretroviral therapy.
    Ananworanich J; Nuesch R; Teeratakulpisarn S; Srasuebkul P; Chuenyam T; Siangphoe U; Ungsedhaphand C; Phanuphak P; Ruxrungtham K
    J Acquir Immune Defic Syndr; 2003 Apr; 32(5):570-2. PubMed ID: 12679711
    [No Abstract]   [Full Text] [Related]  

  • 6. Rebound of HIV-1 viral load after suppression to very low levels.
    Staszewski S; Miller V; Sabin C; Berger A; Hill AM; Phillips AN
    AIDS; 1998 Dec; 12(17):2360. PubMed ID: 9863886
    [No Abstract]   [Full Text] [Related]  

  • 7. CCR5Delta32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response.
    Brumme ZL; Chan KJ; Dong W; Hogg R; O'Shaughnessy MV; Montaner JS; Harrigan PR
    AIDS; 2001 Nov; 15(17):2259-66. PubMed ID: 11698699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Status of anti-HIV-1 chemotherapy in Japan.
    Oishi T; Sugiura W; Matsuda M; Abumi H; Okano A; Yamada K; Koike M; Taki M; Ishikawa M; Miura T; Fukutake K; Gouchi K; Ajisawa A; Iwamoto A; Hanabusa H; Mimaya J; Takamatsu J; Takata N; Kakishita E; Higasa S; Yoshioka A; Kashiwagi S; Shirahata A; Nagai Y
    Jpn J Infect Dis; 1999 Apr; 52(2):51-2. PubMed ID: 10817968
    [No Abstract]   [Full Text] [Related]  

  • 9. Vaccination and HIV-1 replication during highly active antiretroviral therapy.
    Kroon FP; Beersma MF; Kroes AC; Groeneveld PH; van Dissel JT
    AIDS; 1999 Jan; 13(1):135-6. PubMed ID: 10207556
    [No Abstract]   [Full Text] [Related]  

  • 10. Association of heterozygous CCR5Δ32 deletion with survival in HIV-infection: A cohort study.
    Ruiz-Mateos E; Tarancon-Diez L; Alvarez-Rios AI; Dominguez-Molina B; Genebat M; Pulido I; Abad MA; Muñoz-Fernandez MA; Leal M
    Antiviral Res; 2018 Feb; 150():15-19. PubMed ID: 29221798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of NNRTI compared to PI-based highly active antiretroviral therapy on CCR5 receptor expression, beta-chemokines and IL-16 secretion in HIV-1 infection.
    Burton CT; Hardy GA; Sullivan AK; Nelson MR; Gazzard B; Gotch FM; Imami N
    Clin Exp Immunol; 2002 Nov; 130(2):286-92. PubMed ID: 12390317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tribulations and trials in HIV disease, Part 2.
    Boyle BA
    AIDS Read; 2006 Jun; 16(6):291-4. PubMed ID: 16795918
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
    Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
    Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
    Hoffmann F; Funk M; Linde R; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH; Wintergerst U
    Eur J Med Res; 2002 Jul; 7(7):330-4. PubMed ID: 12176683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy.
    Lathey JL; Tierney C; Chang SY; D'Aquila RT; Bettendorf DM; Alexander HC; Santini CD; Hughes AM; Barroga CF; Spector SA; Landes JE; Hammer SM; Katzenstein DA
    J Infect Dis; 2001 Dec; 184(11):1402-11. PubMed ID: 11709782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of CCR5 genetic polymorphism and HIV-1 subtype in antiretroviral response in Brazilian HIV-1-infected patients.
    Accetturi CA; Pardini R; Novaes Pinto GH; Turcato G; Lewi DS; Diaz RS
    J Acquir Immune Defic Syndr; 2000 Aug; 24(4):399-400. PubMed ID: 11015158
    [No Abstract]   [Full Text] [Related]  

  • 17. T-cell modification. Cells genetically modified to resist HIV in 12 people.
    AIDS Policy Law; 2014 Apr; 29(5):1. PubMed ID: 24855699
    [No Abstract]   [Full Text] [Related]  

  • 18. Salvage therapy for patients failing their current antiretroviral regimen.
    Albrecht MA
    AIDS Clin Rev; 2000-2001; ():139-91. PubMed ID: 10999220
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of CCR5 chemokine receptor gene in vertical human immunodeficiency virus type 1 transmission and disease progression.
    Esposito S; Zehender G; Zuccotti GV; Vegni C; Galli L; Vecchi V; Agostoni C; Rancilio L; De Maddalena C; Clerici M; Principi N
    Pediatr Infect Dis J; 1998 Sep; 17(9):847-9. PubMed ID: 9779780
    [No Abstract]   [Full Text] [Related]  

  • 20. CCR5 inhibitors: up and coming new agents.
    O'Neal R
    BETA; 2007; 19(2):15-9. PubMed ID: 17489112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.